Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Misses Expectations By $0.02 EPS

Neumora Therapeutics (NASDAQ:NMRA) announced its earnings results on Monday. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.02), Zacks reports.

Neumora Therapeutics Stock Up 4.5%

Shares of NMRA stock traded up $0.03 during mid-day trading on Monday, reaching $0.69. The company’s stock had a trading volume of 1,213,234 shares, compared to its average volume of 2,563,140. The company’s 50 day simple moving average is $0.92 and its 200-day simple moving average is $4.64. Neumora Therapeutics has a 12-month low of $0.62 and a 12-month high of $17.19. The firm has a market capitalization of $112.01 million, a PE ratio of -0.37 and a beta of 2.96.

Analyst Upgrades and Downgrades

NMRA has been the topic of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $5.00 target price on shares of Neumora Therapeutics in a research report on Thursday, April 10th. Bank of America restated an “underperform” rating and set a $1.00 target price (down previously from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 target price on shares of Neumora Therapeutics in a research report on Tuesday, March 4th. Guggenheim lowered shares of Neumora Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, March 7th. Finally, William Blair downgraded shares of Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $9.29.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.